Filing Details
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:SNDX
Syndax Pharmaceuticals Inc (SNDX) Reports Material Event to SEC
Filing Details Syndax Pharmaceuticals Inc (NASDAQ:SNDX) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market Context…
Market Context
Syndax Pharmaceuticals Inc's stock currently trades at $24.13 with a market capitalization of $1.8B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Syndax Pharmaceuticals Inc's stock.
All SEC filings for Syndax Pharmaceuticals Inc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SNDX Stock Page
Frequently Asked Questions
Where can I read SNDX's SEC filings?
Browse all filings on our SNDX SEC filings page.
What types of SEC filings does Syndax Pharmaceuticals Inc file?
Public companies like Syndax Pharmaceuticals Inc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.